Testing effectiveness (Phase 2)Study completedNCT03439280
What this trial is testing
Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Who this might be right for
Relapsed/RefractoryMultiple Myeloma
Millennium Pharmaceuticals, Inc. 50